Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 7/20 | 0.58 |
| ▸ | CES1 | P23141 | 7/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.46 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6061322 | 0.84 | CES1 (0.62) | CES2CES1ALDH1A1LMNACA1 | |
| SCHEMBL27549712 | 0.82 | CES2 (0.64) | CES2CES1TSHRALDH1A1LMNA | |
| SCHEMBL8536724 | 0.82 | CES1 (0.59) | CES2CES1ALDH1A1LMNACA1 | |
| SCHEMBL28294448 | 0.80 | CES2 (0.65) | CES2CES1TSHRALDH1A1LMNA | |
| SCHEMBL108932 | 0.79 | CES2 (0.52) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL9362108 | 0.78 | CES1 (0.58) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL105950 | 0.77 | — | — | |
| SCHEMBL10308350 | 0.76 | CA1 (0.33) | CA1 | |
| SCHEMBL108642 | 0.75 | CES1 (1.00) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL13967825 | 0.74 | CES2 (0.52) | CES2CES1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115461147-A | Curing catalyst and resin composition | 广荣化学株式会社 | 2022-12-09 | — | — | CN | claimed |
| CN-112088336-A | Composition for forming resist underlayer film and pattern forming method | 三菱瓦斯化学株式会社 | 2020-12-15 | — | — | CN | claimed |
| CN-112041705-A | Optical component-forming composition and cured product thereof | 三菱瓦斯化学株式会社 | 2020-12-04 | — | — | CN | claimed |
| CN-112005168-A | Resist underlayer film forming composition, underlayer film for lithography, and pattern forming method | 三菱瓦斯化学株式会社 | 2020-11-27 | — | — | CN | claimed |
| CN-111164511-A | Composition for lithography, pattern formation method, and compound | 学校法人关西大学 | 2020-05-15 | — | — | CN | claimed |
| CN-107474826-A | Red iridium phosphor material, its preparation method and the application of a kind of Nitrogen-Containing Heterocyclic Ligand | 烟台显华化工科技有限公司 | 2017-12-15 | — | — | CN | claimed |
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| CN-118234772-A | Curable composition, cured product, and catalyst for curing blocked isocyanate compound | 广荣化学株式会社 | 2024-06-21 | — | — | CN | disclosed |
| US-5834151-A | EXPOSING IMAGING LAYER TO FORM MIRROR IMAGE USING THERMAL TRANSFER; HEAT SENSITIVE RECORDING | KONICA CORPORATION (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0798129-A1 | Image forming method | KONICA CORPORATION (JP) | 1997-10-01 | — | — | EP | disclosed |
| WO-1997028135-A1 | 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-08-07 | — | — | WO | disclosed |
| US-4180386-A | ANTIKNOCK FUEL ADDITIVES | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | CES2 60/4885CES1 73/4885HDAC3 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.